Top

Published in:

01-06-2022 | Echocardiography

Combined pre- and post-capillary pulmonary hypertension in left heart disease

Authors: M. Riccardi, M. Pagnesi, E. Sciatti, C. M. Lombardi, R. M. Inciardi, M. Metra, E. Vizzardi

Published in: Heart Failure Reviews | Issue 1/2023

Abstract

Patients with heart failure (HF) often have pulmonary hypertension (PH), which is mainly post-capillary; however, some of them also develop a pre-capillary component. The exact mechanisms leading to combined pre- and post-capillary PH are not yet clear, but the phenomenon seems to start from a passive transmission of increased pressure from the left heart to the lungs, and then continues with the remodeling of both the alveolar and vascular components through different pathways. More importantly, it is not yet clear which patients are predisposed to develop the disease. These patients have some characteristics similar to those with idiopathic pulmonary arterial hypertension (e.g., young age and frequent incidence in female gender), but they share cardiovascular risk factors with patients with HF (e.g., obesity and diabetes), with both reduced and preserved ejection fraction. Thanks to echocardiography parameters and newly introduced scores, more tools are available to distinguish between idiopathic pulmonary arterial hypertension and combined PH and to guide patients’ management. It may be hypothesized to treat patients in whom the pre-capillary component is predominant with specific therapies such as those for idiopathic pulmonary arterial hypertension; however, no adequately powered trials of PH-specific treatment are available in combined PH. Early evidence of clinical benefit has been proven in some trials on phosphodiesterase type 5 inhibitors, while data on prostacyclin analogues, endothelin-1 receptor antagonists, and soluble guanylate cyclase stimulators are still controversial.

Hassoun PM (2021) Pulmonary arterial hypertension. N Engl J Med 385:2361–2376. https://doi.org/10.1056/NEJMra2000348CrossRef

Rosenkranz S, Gibbs JSR, Wachter R et al (2016) Left ventricular heart failure and pulmonary hypertension. Eur Heart J 37:942–954. https://doi.org/10.1093/eurheartj/ehv512CrossRef

Dixon DD, Trivedi A, Shah SJ (2016) Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. Heart Fail Rev 21:285–297. https://doi.org/10.1007/s10741-015-9523-6CrossRef

Rosenkranz S, Kramer T, Gerhardt F et al (2019) Pulmonary hypertension in HFpEF and HFrEF: pathophysiology, diagnosis, treatment approaches. Herz 44(6):483–490. https://doi.org/10.1007/s00059-019-4831-6CrossRef

Gorter TM, Hoendermis ES, van Veldhuisen DJ et al (2016) Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail 18:1472. https://doi.org/10.1002/ejhf.630CrossRef

Galiè N, Humbert M, Vachiery J-L et al (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 37(1):67–119. https://doi.org/10.1093/eurheartj/ehv317CrossRef

Maron BA, Hess E, Maddox TM et al (2016) Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affair clinical assessment, reporting and tracking program. Circulation 133:1240–1248. https://doi.org/10.1161/CIRCULATIONAHA.115.020207CrossRef

Kolte D, Lakshmanan S, Jankowich MD, Brittain EL, Maron BA, Choudhary G (2018) Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis. J Am Heart Assoc 7:e009729. https://doi.org/10.1161/JAHA.118.009729CrossRef

Yaghi S, Novikov A, Trandafirescu T (2020) Clinical update on pulmonary hypertension. J Investig Med 68(4):821–827. https://doi.org/10.1136/jim-2020-001291CrossRef

10.

Palazzini M, Dardi F, Manes A et al (2018) Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes. Eur J Heart Fail 20:248–255. https://doi.org/10.1002/ejhf.860CrossRef

11.

Vachiéry JL, Tedford RJ, Rosenkranz S et al (2019) Pulmonary hypertension due to left heart disease. Eur Respir J. https://doi.org/10.1183/13993003.01897-2018CrossRef

12.

Bradley AM, Gabor K, Anjali V et al (2020) Cardiopulmonary hemodynamics in pulmonary hypertension and heart failure: JACC review topic of the week. J Am Coll Cardiol 76(22):2671–2681. https://doi.org/10.1016/j.jacc.2020.10.007CrossRef

13.

Sugimoto K, Yoshihisa A et al (2020) Significance of pulmonary vascular resistance and diastolic pressure gradient on the new definition of combined post-capillary pulmonary hypertension. Int Heart J 61:301–307. https://doi.org/10.1536/ihj.19-476CrossRef

14.

Maron BA, Kovacs G, Vaidya A et al (2020) Cardiopulmonary hemodynamics in pulmonary hypertension and heart failure. J Am Coll Cardiol 76:2671–2681. https://doi.org/10.1016/j.jacc.2020.10.007CrossRef

15.

Moraes DL, Colucci WS, Givertz MM (2000) Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 102(14):1718–1723. https://doi.org/10.1161/01.CIR.102.14.1718CrossRef

16.

Azarbar S, Dupuis J (2014) Lung capillary injury and repair in left heart disease: a new target for therapy? Clin Sci 127(2):65–76. https://doi.org/10.1042/CS20130296]CrossRef

17.

Saouti N, Westerhof N, Postmus PE, Vonk-Noordegraaf A (2010) The arterial load in pulmonary hypertension. Eur Respir Rev 19(117):197–203. https://doi.org/10.1183/09059180.00002210CrossRef

18.

Chen Y, Guo H, Xu D et al (2012) Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease. Hypertension 59(6):1170–1178. https://doi.org/10.1161/HYPERTENSIONAHA.111.186072CrossRef

19.

Yehuda OB, Rubin LJ (2016) Pulmonary hypertension overlap syndrome, a real entity? JACC 68(4):379–81380. https://doi.org/10.1016/j.jacc2016.05.045CrossRef

20.

Assad TR, Hemnes AR, Larkin EK et al (2016) Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension. J Am Coll Cardiol 68(23):2525–2536. https://doi.org/10.1016/j.jacc.2016.09.942CrossRef

21.

Pugh ME, Robbins IM, Rice TW, West J, Newman JH, Hemnes AR (2011) Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Hear Lung Transplant 30(8):904–911. https://doi.org/10.1016/j.healun.2011.02.016CrossRef

22.

West J, Niswender KD, Johnson JA et al (2013) A potential role for insulin resistance in experimental pulmonary hypertension. Eur Respir J 41(4):861–871. https://doi.org/10.1183/09031936.00030312CrossRef

23.

Hyman L, Howard L, Hauth TA et al (1989) Endothelin produces pulmonary vasoconstriction and systemic vasodilatation. J Appl Physiol 66(2):1008–1012. https://doi.org/10.1152/jappl.1989.66.2.1008CrossRef

24.

Hassoun P, Thappa V, Landman M et al (1992) endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. Proc Soc Exp Biol Med 199(2):165–170. https://doi.org/10.3181/00379727-199-43342CrossRef

25.

Van Duin RWB, Stam K, Cai Z et al (2019) Transition from post capillary pulmonary hypertension to combined pre- and post-capillary pulmonary hypertension in swine: a key role for endothelin. J Physiol. https://doi.org/10.1113/JP275987CrossRef

26.

Meoli DF, Ru SuY, Brittain EV, Robbins IV et al (2018) the transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension. Pulm Circ 8(1):1–8. https://doi.org/10.1177/2045893217745019CrossRef

27.

Yang J, Li X, Morrel NW (2014) ID protein in the vasculature: from molecular biology to cardiopulmonary medicine. Cardiovasc Res 104:388–398. https://doi.org/10.1093/cvr/cvu215CrossRef

28.

Morty RE et al (2007) Dysregulated bone morphogenetic protein signalling in monocrotaline-induced pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 27:1072–1078. https://doi.org/10.1161/ATVBAHA.107.141200CrossRef

29.

Yang Y et al (2013) ID proteins are critical downstream effectors of BMP signalling in human pulmonary arterial smooth muscle cell. Am J Physiol Lung Cell Mol Physiol 305:312–321. https://doi.org/10.1152/ajplung.00054.2013CrossRef

30.

Arwood MJ, Vahabi N, Lteif C et al (2019) Transcriptome-wide analysis associates ID2 expression with combined pre- and post-capillary pulmonary hypertension. Sci Rep 9(1):19572. https://doi.org/10.1038/s41598-019-55700-yCrossRef

31.

Miller WL, Grill DE, Borlaug BA (2013) Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Hear Fail 1(4):290–299. https://doi.org/10.1016/j.jchf.2013.05.001CrossRef

32.

Leopold JA (2016) Biological phenotyping of combined post-capillary and pre-capillary pulmonary hypertension: focus on pulmonary vascular remodeling. J Am Coll Cardiol 68(23):2537–2539. https://doi.org/10.1016/j.jacc.2016.10.013CrossRef

33.

Opitz CF, Hoeper MM, Gibbs JSR et al (2016) Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 68:368–378. https://doi.org/10.1016/j.jacc.2016.05.047CrossRef

34.

Ryan JJ, Rich JD, Thiruvoipati T, Swamy R, Kim GH, Rich S (2012) Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J 163(4):589–594. https://doi.org/10.1016/j.ahj.2012.01.024CrossRef

35.

Robbins IM, Hemnes AR, Pugh ME et al (2014) High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Hear Fail 7(1):116–122. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000468CrossRef

36.

Fujimoto N, Borlaug BA, Lewis GD et al (2013) Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation 127(1):55–62. https://doi.org/10.1161/CIRCULATIONAHA.112.111302CrossRef

37.

Pellegrini P, Rossi A et al (2014) Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. Chest J 5:1064–1070. https://doi.org/10.1378/chest.13-1510CrossRef

38.

Ghio S, Schirinzi S, Pica S (2015) Pulmonary arterial compliance: how and why should we measure it? Glob Cardiol Sci Pract 2015(4):58. https://doi.org/10.5339/gcsp.2015.58CrossRef

39.

Ghio S, Crimi G, Pica S et al (2017) Persistent abnormalities in pulmonary arterial compliance after heart transplantation in patients with combined post-capillary and pre-capillary pulmonary hypertension. PLoS ONE 12(11):e0188383. https://doi.org/10.1371/journal.pone.0188383CrossRef

40.

Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S (2011) Inaccuracy of Doppler echocardiography estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest 139(5):988–993. https://doi.org/10.1378/chest.10-1269CrossRef

41.

Damy T et al (2012) Prevalence of association with, and prognostic value of tricuspid annular plane systolic excursion (TAPSE) among out-patients referred for the evaluation of heart failure. J Card Fail 18(3):216–225. https://doi.org/10.1016/j.cardfail.2011.12.003CrossRef

42.

Ghio S, Pica S, Klersy C et al (2016) Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy. Open Heart 3:e000408. https://doi.org/10.1136/openhrt-2016-000408CrossRef

43.

Guazzi M, Bandera F, Pelissero G et al (2013) Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. Am J Physiol Heart Circ Physiol 305:H1373–H1381. https://doi.org/10.1152/ajpheart.00157.2013CrossRef

44.

Gorter TM, van Veldhuisen DJ et al (2018) Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs post-capillary pulmonary hypertension. Eur Heart J Cardiovasc Imaging 19:425–432. https://doi.org/10.1093/ehjci/jex133CrossRef

45.

Todaro M, Carery S et al (2020) Echocardiographic evaluation of right ventricular-arterial coupling in pulmonary hypertension. Am J Cardiovasc Dis 10(4):272–283. PMID: 33224574; PMCID: PMC7675169

46.

Gerges M, Gerges C, Pistritto AM et al (2015) Pulmonary hypertension in heart failure epidemiology, right ventricular function, and survival. Am J Respir Crit Care Med 192(10):1234–1246. https://doi.org/10.1164/rccm.201503-0529OCCrossRef

47.

Santiago-Vacas E, Lupón J, Gavidia-Bovadilla G, Gual-Capllonch F, de Antonio M, Domingo M, Núñez J, Zamora E, Teis A, Moliner P, Codina P, Santesmases J, Bayes-Genis A (2020) Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15-year prospective longitudinal trajectories in survivors. Eur J Heart Fail 22(7):1214–1225. https://doi.org/10.1002/ejhf.1862. Epub 2020 May 25 PMID: 32452102CrossRef

48.

Arkles JS, Opotowsky AR, Ojeda J et al (2011) Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med 183:268–276. https://doi.org/10.1164/rccm.201004-0601OCCrossRef

49.

Janei C, Kadar R et al (2021) Role of 3D echocardiography-determined atrial volumes in distinguishing between pre-capillary and post-capillary pulmonary hypertension. ESC Heart Failure 8:3975–3983. https://doi.org/10.1002/ehf2.13496CrossRef

50.

Held M, Weiner S, Walthelm J et al (2021) Funktionelle charakterisierung von patienten mit isoliert postkapillärer oder kombiniert post- und präkapillärer pulmonaler hypertonie. Dtsch Med Wochenschr 146:e88–e94. https://doi.org/10.1055/a-1555-0345CrossRef

51.

Scalia M, Scalia IG, Kierle R et al (2016) ePLAR—the echocardiographic pulmonary to left atrial ratio—a novel non-invasive parameter to differentiate pre-capillary and post-capillary pulmonary hypertension. Int J Cardiol 212:379–386. https://doi.org/10.1016/j.ijcard.2016.03.035CrossRef

52.

Cameli M, Mandoli GE, Loiacono F et al (2016) Left atrial strain: a new parameter for assessment of left ventricular filling pressure. Heart Fail Rev 21(1):65–76. https://doi.org/10.1007/s10741-015-9520-9CrossRef

53.

Cameli M, Sparla S, Losito M et al (2016) Correlation of left atrial strain and Doppler measurements with invasive measurement of left ventricular end-diastolic pressure in patients stratified for different values of ejection fraction. Echocardiography (Mount Kisco, NY) 33(3):398–405. https://doi.org/10.1111/echo.13094CrossRef

54.

Cameli M, Lisi M, Mondillo S et al (2010) Left atrial longitudinal strain by speckle tracking echocardiography correlates well with left ventricular filling pressures in patients with heart failure, Cardiovasc. Ultrasound. https://doi.org/10.1186/1476-7120-8-14. PMID: 20409332; PMCID: PMC2868789CrossRef

55.

Zanaboni J, Panizza A, Marino P (2021) Left atrial conduit function modulates right ventricular afterload, exercise capacity and survival in heart failure patients. J Cardiovasc Med. https://doi.org/10.2459/JCM.0000000000001171CrossRef

56.

Venkateshvaran A, Manouras A, Kjellström B et al (2019) The additive value of echocardiographic pulmonary to left atrial global strain ratio in the diagnosis of pulmonary hypertension. Int J Cardiol 1(292):205–210. https://doi.org/10.1016/j.ijcard.2019.05.025CrossRef

57.

Sanz J, Kariisa M, Dellegrottaglie S et al (2009) Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. JACC Cardiovasc Imaging 2(3):286–295. https://doi.org/10.1016/j.jcmg.2008.08.007CrossRef

58.

Habert P, Capron T, Hubert S et al (2020) Quantification of right ventricular extracellular volume in pulmonary hypertension using cardiac magnetic resonance imaging. Diagn Interv Imaging 101:311–320. https://doi.org/10.1016/j.diii.2019.12.008CrossRef

59.

Johns CS, Wild JM et al (2018) Identifying at-risk patients with combined pre- and post-capillary pulmonary hypertension using interventricular septal angle at cardiac MRI. Radiology 289:61–68. https://doi.org/10.1148/radiol.2018180120CrossRef

60.

Opotowsky AR, Ojeda J, Rogers F et al (2012) A simple echocardiographic prediction rule for hemodynamics in pulmonary hypertension. Circ Cardiovasc Imaging 5(6):765–775. https://doi.org/10.1161/CIRCIMAGING.112.976654CrossRef

61.

D’Alto M, Romeo E, Argiento P et al (2015) Echocardiographic prediction of pre- versus postcapillary pulmonary hypertension. J Am Soc Echocardiogr 28(1):108–115. https://doi.org/10.1016/j.echo.2014.09.004CrossRef

62.

Naeije R, D’Alto M (2016) The diagnostic challenge of group 2 pulmonary hypertension. Prog Cardiovasc Dis 59(1):22–29. https://doi.org/10.1016/j.pcad.2016.05.003CrossRef

63.

McDonagh TA, Metra M, Adamo M et al (2021) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021(00):1–128. https://doi.org/10.1093/eurheartj/ehab368CrossRef

64.

Braun S, Schrötter H, Schmeisser A, Strasser RH (2007) Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension. Int J Cardiol 115(1):67–72. https://doi.org/10.1016/j.ijcard.2006.01.067CrossRef

65.

Von Scheidt W, Costard-Jaeckle A, Stempfle HU et al (2006) Prostaglandin E1 testing in heart failure-associated pulmonary hypertension enables transplantation: the PROPHET study. J Hear Lung Transplant 25(9):1070–1076. https://doi.org/10.1016/j.healun.2006.04.011CrossRef

66.

Yui Y, Nakajima H, Kawai C, Murakami T (1982) Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol 50(2):320–324. https://doi.org/10.1016/0002-9149(82)90183-7CrossRef

67.

Califf RM, Adams KF, McKenna WJ et al (1997) A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 134(1):44–54. https://doi.org/10.1016/S0002-8703(97)70105-4CrossRef

68.

Sütsch G, Kiowski W, Yan XW et al (1998) Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98(21):2262–2268. https://doi.org/10.1161/01.CIR.98.21.2262CrossRef

69.

Packer M, McMurray JJV, Krum H et al (2017) Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronich heart failure: primary results of the ENABLE trials. JACC Heart Fail 5:317–326. https://doi.org/10.1016/j.jchf.2017.02.021CrossRef

70.

Vachléry JL, Delcroix, Al-Hiti H et al (2018) Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. https://doi.org/10.1183/13993003.01886-2017

71.

ClinicalTrials.gov Identifier: NCT03153111. (2017)

72.

Guazzi M, Samaja M, Arena R et al (2007) Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 50:2136–2144. https://doi.org/10.1016/j.jacc.2007.07.078CrossRef

73.

Guazzi M, Vicenzi M, Arena R (2011) Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124:164–174. https://doi.org/10.1161/CIRCULATIONAHA.110.983866CrossRef

74.

Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD (2004) The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 44(12):2339–2348. https://doi.org/10.1016/j.jacc.2004.09.041CrossRef

75.

Redfield MM, Chen HH, Borlaug BA et al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction. JAMA 309(12):1268. https://doi.org/10.1001/jama.2013.2024CrossRef

76.

Hoendermis ES, Liu LC, Hummel YM, Van der Meer P, De Boer RA, Berger RMF et al (2015) ELects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 36(36):2565–2573. https://doi.org/10.1093/eurheartj/ehv336CrossRef

77.

Cooper TJ, Cleland JGF, Guazzi M et al (2022) Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (SilHF) study. Eur J Heart Fail

78.

Kramer T, Dumitrescu D, Gerhardt F et al (2019) Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. Int J Cardiol 283:152–158. https://doi.org/10.1016/j.ijcard.2018.12.078CrossRef

79.

Behr J, Nathan SD, Wuyts WA, Mogulkoc Bishop N, Bouros DE, Antoniou K, Guiot J, Kramer MR, Kirchgaessler KU, Bengus M, Gilberg F, Perjesi A, Harari S, Wells AU (2021) Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 9(1):85–95. https://doi.org/10.1016/S2213-2600(20)30356-8. Epub 2020 Aug 18. Erratum in: Lancet Respir Med. 2021 Apr;9(4):e38. PMID: 32822614

80.

Barnes H, Brown Z, Burns A, Williams T (2019) Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev 1(1):CD012621. https://doi.org/10.1002/14651858.CD012621.pub2. PMID: 30701543; PMCID: PMC6354064CrossRef

81.

Kido K, Coons JC (2019) Efficacy and safety of the use of pulmonary arterial hypertension pharmacotherapy in patients with pulmonary hypertension secondary to left heart disease: a systematic review. Pharmacotherapy 39(9):929–945. https://doi.org/10.1002/phar.2314. PMID: 31349390CrossRef

82.

Bonderman D, Ghio S, Felix SB et al (2013) Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128:502–511. https://doi.org/10.1161/CIRCULATIONAHA.113.001458CrossRef

83.

Bonderman D, Pretsch I, Steringer-Mascherbauer R et al (2014) Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest 146:1274–1285. https://doi.org/10.1378/chest.14-0106CrossRef

84.

Armstrong PW, Pieske B, Anstrom KJ et al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382:1883–1893. https://doi.org/10.1056/NEJMoa1915928CrossRef

85.

Verschure DO et al (2016) Cardiac sympathetic activity in chronic heart failure: cardiac 123I-mIBG scintigraphy to improve patient selection for ICD implantation. Neth Heart J 24:701–708. https://doi.org/10.1007/s12471-016-0902-yCrossRef

86.

Zhang H, Zhang J, Chen M et al (2019) Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure: the PADN-5 study. JACC Cardiovasc Interv 12(3):274–284. https://doi.org/10.1016/j.jcin.2018.09.021CrossRef

87.

Hoeper MM (2020) Pulmonary artery denervation, the new kid on the block? JACC 76(8):927–929. https://doi.org/10.1016/j.jacc.2020.06.067CrossRef

88.

Constantine A, Dimopoulos K (2021) Pulmonary artery denervation for pulmonary arterial hypertension. Trends Cardiovasc Med 31(4):252–260. https://doi.org/10.1016/j.tcm.2020.04.005CrossRef

Title: Combined pre- and post-capillary pulmonary hypertension in left heart disease
Authors: M. Riccardi
M. Pagnesi
E. Sciatti
C. M. Lombardi
R. M. Inciardi
M. Metra
E. Vizzardi
Publication date: 01-06-2022
Publisher: Springer US
Keywords: Echocardiography
Phosphodiesterase-5 Inhibitor
Pulmonary Hypertension
Heart Failure
Echocardiography
Pulmonary Hypertension
Pulmonary Hypertension
Pulmonary Hypertension
Riociguat
Published in: Heart Failure Reviews / Issue 1/2023
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-022-10251-9

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Combined pre- and post-capillary pulmonary hypertension in left heart disease

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Echocardiographic scores for biventricular repair risk prediction of congenital heart disease with borderline left ventricle: a review

Skeletal muscle abnormalities in heart failure with preserved ejection fraction

Cardiometabolic-based chronic disease: adiposity and dysglycemia drivers of heart failure

PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis

The value of myocardial strain imaging in the evaluation of patients with repaired Tetralogy of Fallot: a review of the literature

Relationships among norepinephrine levels, exercise capacity, and chronotropic responses in heart failure patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page